Focused On-demand Library for Protein regulator of cytokinesis 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O43663

UPID:

PRC1_HUMAN

Alternative names:

Alternative UPACC:

O43663; A6NC44; B4DLR1; H9KV59; Q9BSB6

Background:

Protein Regulator of Cytokinesis 1 (PRC1) is a pivotal component in cell division, specifically in the process of cytokinesis. It functions by cross-linking antiparallel microtubules, facilitating the formation of the midzone essential for cell division. PRC1's role extends to the localization of KIF14 and the recruitment of PLK1 to the spindle, crucial for cell cycle progression. Its interaction with RACGAP1 and ECT2 underscores its importance in cytokinesis.

Therapeutic significance:

Understanding the role of Protein Regulator of Cytokinesis 1 could open doors to potential therapeutic strategies. Its involvement in critical cell division processes and its oncogenic potential in bladder cancer highlight its significance as a target for cancer therapy. By modulating PRC1 activity, it may be possible to develop novel treatments for cancer, emphasizing the need for further research into its mechanisms and interactions.